Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment

Inclusion Criteria: 1. Aged 35-80 years; 2. Stroke duration within 2 weeks to 6 months post-onset; 3. Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score \< 26; 4. Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.); 5. No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study; 6. Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form. Exclusion Criteria: 1. Unstable vital signs or life-threatening comorbidities; 2. Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.); 3. History of epilepsy or epileptic seizures; 4. Pregnant or lactating women; 5. Concurrent use of other medications affecting cognitive function; 6. Allergy to the study intervention device or history of serious adverse reactions; 7. Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.); 8. Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.